MAY 26, 2017 10:49 AM PDT

FDA Approved Cancer Drug Based on Mutation, Not Location

WRITTEN BY: Xuan Pham

For the first time, the US FDA approved a cancer drug for patients based on presence of genetic biomarkers. Whereas cancer drugs have been traditionally been approved based on the location of the tumor, Keytruda (pembrolizumab) is approved for cancer patients with genetic defects classified as “microsatellite instability” or “mismatch repair” deficiencies.

"KEYTRUDA binds to the PD-­1 receptor and blocks its interaction with PD-­L1 and PD-­L2, which helps restore the immune response." - Keytruda.com

"This is an important first for the cancer community," said Richard Pazdur, acting director of the Office of Hematology and Oncology Products in the FDA's Center for Drug Evaluation and Research and director of the FDA's Oncology Center of Excellence. "Until now, the FDA has approved cancer treatments based on where in the body the cancer started - for example, lung or breast cancers. We have now approved a drug based on a tumor's biomarker without regard to the tumor's original location."

Keytruda is a humanized antibody that works as a second-line immunotherapy agent to destroy the cancer. This drug targets the programmed cell death 1 (PD-1) receptor, a protein that’s responsible for preventing the immune system from attacking its own cells. Cancers can take advantage of this system by making its own proteins that bind to PD-1, which shuts down the body’s ability to kill the cancer. As an immunotherapy, pembrolizumab boosts the body’s ability to kill the cancer again. The drug is already approved for the treatment of several types of cancer, including non-small cell lung cancer, melanoma, and some head and neck cancers, and even mesothelioma.

But the new approval could significantly expand uses of this drug. In particular, Keytruda may now be used to treat any solid tumor as long as the patients have the indicated biomarkers: microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR). These types of deficiencies are estimated to be present in about 4 percent of cancers, including colorectal, endometrial, and gastrointestinal cancers.

Notably, the drug’s new indication would expand access to cancer patients with solid tumors that have progressed despite treatment and for which there are no other therapy. For colorectal cancer, this means patients who have exhausted their chemotherapy defenses with drugs such as fluoropyrimidine, oxaliplatin, and irinotecan, Keytruda can be a new option.

“The FDA’s approval of this new indication for Keytruda further supports Merck’s commitment to helping people with difficult-to-treat cancers,” said Roger M. Perlmutter, president of Merck Research Laboratories, the drug’s manufacturer.

 

About the Author
  • I am a human geneticist, passionate about telling stories to make science more engaging and approachable. Find more of my writing at the Hopkins BioMedical Odyssey blog and at TheGeneTwist.com.
You May Also Like
APR 11, 2021
Genetics & Genomics
Trial Shows Personalized Cancer Vaccines are Safe
APR 11, 2021
Trial Shows Personalized Cancer Vaccines are Safe
Vaccines are mostly known as tools to prevent illness. But cancer vaccines are a bit different, and aim to treat existin ...
APR 14, 2021
Cancer
Fighting back against medulloblastoma with naturally-occurring compound
APR 14, 2021
Fighting back against medulloblastoma with naturally-occurring compound
Renewed hope for young children with medulloblastoma comes in the form of a research paper published from the Queen Mary ...
MAY 02, 2021
Cancer
Evaluating early learning skills in child survivors of retinoblastoma
MAY 02, 2021
Evaluating early learning skills in child survivors of retinoblastoma
A report published recently in the Journal of Clinical Oncology highlights the need for early intervention resources for ...
MAY 20, 2021
Cancer
High red meat consumption and low education level associated with early-onset colorectal cancer
MAY 20, 2021
High red meat consumption and low education level associated with early-onset colorectal cancer
Research published recently in JNCI Cancer Spectrum reports that higher red meat and alcohol consumption, as well as low ...
MAY 26, 2021
Genetics & Genomics
Connecting Bacterial Genes to Human Disease
MAY 26, 2021
Connecting Bacterial Genes to Human Disease
This kind of research gets us closer to using fecal samples to get a snapshot of the microbiome, and make disease risk p ...
JUN 09, 2021
Technology
Computer Program Generates Effective, Clinically-valid Treatment Plans for Cancer Patients
JUN 09, 2021
Computer Program Generates Effective, Clinically-valid Treatment Plans for Cancer Patients
In a recent study published in Nature Medicine, researchers at the Princess Margaret Cancer Centre offer evidence for th ...
Loading Comments...